February 9, 2021 -- Tmunity Therapeutics said it has expanded its T-cell engineered therapy collaboration with the University of Pennsylvania (Penn).
As a result, the biotherapeutics firm will gain further access and rights to certain platform and manufacturing technologies, as well as an exclusive license to a clinical-stage mesothelin chimeric antigen receptor (CAR) T-cell therapy product developed at the university's Center for Cellular Immunotherapies. In addition, Tmunity said it has committed to further fund T-cell engineering research programs at Penn. The company will receive exclusive rights to products and technologies developed by those programs, subject to certain limitations.
What's more, Tmunity will retain certain rights to intellectual property originating from the laboratories of its scientific founders at Penn, including Dr. Carl June, Bruce Levine, PhD, and James Riley, PhD. The company has already licensed four clinical-stage solid tumor CAR T programs created at the university.
Copyright © 2021 scienceboard.net